Which has stronger valuation and earnings, AMGN or ABBV?

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amgen $38.10B 6.28 $7.71B $16.09 27.49 AbbVie $64.39B 7.29 $4.23B $3.54 75.04

Is AMGN or ABBV more profitable?

Amgen has a net margin of 22.95% compared to AbbVie's net margin of 9.80%. Amgen's return on equity of 124.14% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Amgen 22.95% 124.14% 13.18% AbbVie 9.80% -422.07% 14.34%

Does the media favor AMGN or ABBV?

In the previous week, Amgen had 15 more articles in the media than AbbVie. MarketBeat recorded 64 mentions for Amgen and 49 mentions for AbbVie. Amgen's average media sentiment score of 1.19 beat AbbVie's score of 1.13 indicating that Amgen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amgen 49 Very Positive mention(s) 5 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 34 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is GILD or ABBV more profitable?

AbbVie has a net margin of 9.80% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Gilead Sciences -10.64% -2.11% -0.75% AbbVie 9.80% -422.07% 14.34%

Does the media prefer GILD or ABBV?

In the previous week, Gilead Sciences had 44 more articles in the media than AbbVie. MarketBeat recorded 93 mentions for Gilead Sciences and 49 mentions for AbbVie. Gilead Sciences' average media sentiment score of 1.23 beat AbbVie's score of 1.13 indicating that Gilead Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 68 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 34 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger valuation & earnings, MRNA or ABBV?

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Moderna $1.94B 35.81 -$2.82B -$7.99 N/A AbbVie $64.39B 7.29 $4.23B $3.54 75.04

Is MRNA or ABBV more profitable?

AbbVie has a net margin of 9.80% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets Moderna -141.43% -28.30% -19.39% AbbVie 9.80% -422.07% 14.34%

Does the media refer more to MRNA or ABBV?

In the previous week, Moderna had 11 more articles in the media than AbbVie. MarketBeat recorded 60 mentions for Moderna and 49 mentions for AbbVie. AbbVie's average media sentiment score of 1.13 beat Moderna's score of 0.59 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 29 Very Positive mention(s) 6 Positive mention(s) 6 Neutral mention(s) 8 Negative mention(s) 7 Very Negative mention(s) Positive AbbVie 34 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer ABT or ABBV?

In the previous week, AbbVie had 6 more articles in the media than Abbott Laboratories. MarketBeat recorded 49 mentions for AbbVie and 43 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.40 beat AbbVie's score of 1.13 indicating that Abbott Laboratories is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abbott Laboratories 36 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 34 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has stronger valuation & earnings, ABBV or AZN?

Astrazeneca has lower revenue, but higher earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AbbVie $64.39B 7.29 $4.23B $3.54 75.04 Astrazeneca $58.74B 4.36 $10.23B $6.69 24.68

Is ABBV or AZN more profitable?

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity. Company Net Margins Return on Equity Return on Assets AbbVie 9.80% -422.07% 14.34% Astrazeneca 17.02% 31.45% 13.20%

Does the media refer more to ABBV or AZN?

In the previous week, AbbVie had 37 more articles in the media than Astrazeneca. MarketBeat recorded 49 mentions for AbbVie and 12 mentions for Astrazeneca. AbbVie's average media sentiment score of 1.13 beat Astrazeneca's score of 0.31 indicating that AbbVie is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AbbVie 34 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Astrazeneca 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 3 Very Negative mention(s) Neutral

AbbVie (ABBV) Competitors

$265.63 +6.71 (+2.59%)

Closing price 08/19/2026 03:59 PM Eastern

Extended Trading

$263.23 -2.40 (-0.90%)

As of 09:25 AM Eastern

Compare

ABBV vs. AMGN, GILD, MRNA, ABT, and AZN

Should you buy AbbVie stock or one of its competitors? AbbVie's main competitors and comparable companies include Amgen (AMGN), Gilead Sciences (GILD), Moderna (MRNA), Abbott Laboratories (ABT), and Astrazeneca (AZN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does AbbVie compare to Amgen?

Amgen (NASDAQ:AMGN) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Amgen has a net margin of 22.95% compared to AbbVie's net margin of 9.80%. Amgen's return on equity of 124.14% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amgen	22.95%	124.14%	13.18%
AbbVie	9.80%	-422.07%	14.34%

Amgen currently has a consensus target price of $379.36, suggesting a potential downside of 14.24%. AbbVie has a consensus target price of $275.73, suggesting a potential upside of 3.80%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Amgen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amgen	3 Sell rating(s)	14 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.39
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

Amgen has higher earnings, but lower revenue than AbbVie. Amgen is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amgen	$38.10B	6.28	$7.71B	$16.09	27.49
AbbVie	$64.39B	7.29	$4.23B	$3.54	75.04

Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 2.3%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Amgen pays out 62.6% of its earnings in the form of a dividend. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has increased its dividend for 14 consecutive years and AbbVie has increased its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

76.5% of Amgen shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.9% of Amgen shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Amgen has a beta of 0.41, meaning that its stock price is 59% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, meaning that its stock price is 70% less volatile than the broader market.

In the previous week, Amgen had 15 more articles in the media than AbbVie. MarketBeat recorded 64 mentions for Amgen and 49 mentions for AbbVie. Amgen's average media sentiment score of 1.19 beat AbbVie's score of 1.13 indicating that Amgen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amgen	49 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	34 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Amgen and AbbVie tied by winning 10 of the 20 factors compared between the two stocks.

How does AbbVie compare to Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Gilead Sciences has higher earnings, but lower revenue than AbbVie. Gilead Sciences is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gilead Sciences	$30.46B	6.01	$8.51B	-$2.67	N/A
AbbVie	$64.39B	7.29	$4.23B	$3.54	75.04

83.7% of Gilead Sciences shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.3% of Gilead Sciences shares are owned by company insiders. Comparatively, 0.1% of AbbVie shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

AbbVie has a net margin of 9.80% compared to Gilead Sciences' net margin of -10.64%. Gilead Sciences' return on equity of -2.11% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gilead Sciences	-10.64%	-2.11%	-0.75%
AbbVie	9.80%	-422.07%	14.34%

Gilead Sciences presently has a consensus target price of $158.04, indicating a potential upside of 7.07%. AbbVie has a consensus target price of $275.73, indicating a potential upside of 3.80%. Given Gilead Sciences' higher possible upside, equities research analysts plainly believe Gilead Sciences is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gilead Sciences	0 Sell rating(s)	5 Hold rating(s)	24 Buy rating(s)	0 Strong Buy rating(s)	2.83
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

Gilead Sciences pays an annual dividend of $3.28 per share and has a dividend yield of 2.2%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Gilead Sciences pays out -122.8% of its earnings in the form of a dividend. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Gilead Sciences has raised its dividend for 10 consecutive years and AbbVie has raised its dividend for 53 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Gilead Sciences has a beta of 0.32, indicating that its stock price is 68% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

In the previous week, Gilead Sciences had 44 more articles in the media than AbbVie. MarketBeat recorded 93 mentions for Gilead Sciences and 49 mentions for AbbVie. Gilead Sciences' average media sentiment score of 1.23 beat AbbVie's score of 1.13 indicating that Gilead Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gilead Sciences	68 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	34 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Gilead Sciences and AbbVie tied by winning 10 of the 20 factors compared between the two stocks.

How does AbbVie compare to Moderna?

Moderna (NASDAQ:MRNA) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

AbbVie has a net margin of 9.80% compared to Moderna's net margin of -141.43%. Moderna's return on equity of -28.30% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Moderna	-141.43%	-28.30%	-19.39%
AbbVie	9.80%	-422.07%	14.34%

Moderna has a beta of 0.91, indicating that its share price is 9% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market.

AbbVie has higher revenue and earnings than Moderna. Moderna is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Moderna	$1.94B	35.81	-$2.82B	-$7.99	N/A
AbbVie	$64.39B	7.29	$4.23B	$3.54	75.04

75.3% of Moderna shares are held by institutional investors. Comparatively, 70.2% of AbbVie shares are held by institutional investors. 10.8% of Moderna shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Moderna presently has a consensus target price of $59.69, indicating a potential downside of 65.77%. AbbVie has a consensus target price of $275.73, indicating a potential upside of 3.80%. Given AbbVie's stronger consensus rating and higher possible upside, analysts plainly believe AbbVie is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moderna	4 Sell rating(s)	11 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.00
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

In the previous week, Moderna had 11 more articles in the media than AbbVie. MarketBeat recorded 60 mentions for Moderna and 49 mentions for AbbVie. AbbVie's average media sentiment score of 1.13 beat Moderna's score of 0.59 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Moderna	29 Very Positive mention(s)	6 Positive mention(s)	6 Neutral mention(s)	8 Negative mention(s)	7 Very Negative mention(s)	Positive
AbbVie	34 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

AbbVie beats Moderna on 11 of the 17 factors compared between the two stocks.

How does AbbVie compare to Abbott Laboratories?

Abbott Laboratories (NYSE:ABT) and AbbVie (NYSE:ABBV) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, profitability and dividends.

Abbott Laboratories currently has a consensus price target of $118.67, suggesting a potential upside of 3.64%. AbbVie has a consensus price target of $275.73, suggesting a potential upside of 3.80%. Given AbbVie's higher probable upside, analysts clearly believe AbbVie is more favorable than Abbott Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abbott Laboratories	0 Sell rating(s)	4 Hold rating(s)	20 Buy rating(s)	3 Strong Buy rating(s)	2.96
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

Abbott Laboratories has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

In the previous week, AbbVie had 6 more articles in the media than Abbott Laboratories. MarketBeat recorded 49 mentions for AbbVie and 43 mentions for Abbott Laboratories. Abbott Laboratories' average media sentiment score of 1.40 beat AbbVie's score of 1.13 indicating that Abbott Laboratories is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abbott Laboratories	36 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	34 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Abbott Laboratories pays an annual dividend of $2.52 per share and has a dividend yield of 2.2%. AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Abbott Laboratories pays out 81.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Abbott Laboratories has raised its dividend for 54 consecutive years and AbbVie has raised its dividend for 53 consecutive years.

75.2% of Abbott Laboratories shares are owned by institutional investors. Comparatively, 70.2% of AbbVie shares are owned by institutional investors. 0.5% of Abbott Laboratories shares are owned by insiders. Comparatively, 0.1% of AbbVie shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Abbott Laboratories has a net margin of 11.65% compared to AbbVie's net margin of 9.80%. Abbott Laboratories' return on equity of 17.69% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abbott Laboratories	11.65%	17.69%	9.44%
AbbVie	9.80%	-422.07%	14.34%

Abbott Laboratories has higher earnings, but lower revenue than AbbVie. Abbott Laboratories is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abbott Laboratories	$44.33B	4.47	$6.52B	$3.09	37.06
AbbVie	$64.39B	7.29	$4.23B	$3.54	75.04

Summary

Abbott Laboratories beats AbbVie on 12 of the 20 factors compared between the two stocks.

How does AbbVie compare to Astrazeneca?

AbbVie (NYSE:ABBV) and Astrazeneca (NYSE:AZN) are both large-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Astrazeneca has lower revenue, but higher earnings than AbbVie. Astrazeneca is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbbVie	$64.39B	7.29	$4.23B	$3.54	75.04
Astrazeneca	$58.74B	4.36	$10.23B	$6.69	24.68

Astrazeneca has a net margin of 17.02% compared to AbbVie's net margin of 9.80%. Astrazeneca's return on equity of 31.45% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AbbVie	9.80%	-422.07%	14.34%
Astrazeneca	17.02%	31.45%	13.20%

AbbVie currently has a consensus target price of $275.73, suggesting a potential upside of 3.80%. Astrazeneca has a consensus target price of $211.00, suggesting a potential upside of 27.81%. Given Astrazeneca's higher probable upside, analysts plainly believe Astrazeneca is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88
Astrazeneca	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73

70.2% of AbbVie shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, AbbVie had 37 more articles in the media than Astrazeneca. MarketBeat recorded 49 mentions for AbbVie and 12 mentions for Astrazeneca. AbbVie's average media sentiment score of 1.13 beat Astrazeneca's score of 0.31 indicating that AbbVie is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AbbVie	34 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Astrazeneca	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	3 Very Negative mention(s)	Neutral

AbbVie pays an annual dividend of $6.92 per share and has a dividend yield of 2.6%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.6%. AbbVie pays out 195.5% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Astrazeneca pays out 64.9% of its earnings in the form of a dividend. AbbVie has increased its dividend for 53 consecutive years. Astrazeneca is clearly the better dividend stock, given its higher yield and lower payout ratio.

AbbVie has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.26, indicating that its share price is 74% less volatile than the broader market.

Summary

AbbVie beats Astrazeneca on 13 of the 20 factors compared between the two stocks.

Get AbbVie News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABBV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABBV vs. The Competition

Export

Metric	AbbVie	Biotechnology Industry	Healthcare Sector	NYSE Exchange
Market Cap	$469.91B	$3.89B	$7.18B	$24.19B
Dividend Yield	2.76%	3.66%	2.55%	3.73%
P/E Ratio	75.04	11.71	268.94	30.14
Price / Sales	7.29	1,349.97	618.72	19.90
Price / Cash	17.09	102.56	78.23	31.97
Price / Book	-79.77	17.33	13.28	6.84
Net Income	$4.23B	-$12.52M	$3.47B	$1.07B
7 Day Performance	5.74%	4.47%	2.21%	-0.57%
1 Month Performance	4.84%	7.81%	5.29%	2.97%
1 Year Performance	27.26%	63.80%	29.17%	18.26%

AbbVie Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABBV AbbVie	4.8111 of 5 stars	$265.63 +2.6%	$275.95 +3.9%	+29.0%	$469.91B	$64.39B	75.04	57,000	Positive News Analyst Forecast Insider Trade
AMGN Amgen	3.8644 of 5 stars	$411.08 -1.6%	$372.39 -9.4%	+49.7%	$222.54B	$38.10B	25.58	31,500	Trending News Analyst Forecast
GILD Gilead Sciences	4.0966 of 5 stars	$137.10 -0.8%	$158.04 +15.3%	+25.1%	$170.15B	$30.46B	N/A	17,000	Trending News Insider Trade Analyst Revision
MRNA Moderna	1.7026 of 5 stars	$62.69 -1.5%	$42.13 -32.8%	+524.8%	$25.08B	$1.94B	N/A	4,700	Trending News Analyst Upgrade Options Volume Gap Up
ABT Abbott Laboratories	4.6035 of 5 stars	$111.44 +0.2%	$118.67 +6.5%	-12.7%	$192.91B	$44.33B	36.08	115,000	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ABBV) was last updated on 8/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AbbVie (ABBV) Competitors